Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth. Older top-selling drugs, including its blood thinner Eliquis, also helped drive demand in the quarter and offset the decline in revenue from Pfizer's Covid vaccine and antiviral pill to treat the virus, Paxlovid. Here's what the company reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:  Earnings per share: 75 cents adjusted vs. 72 cents expected Revenue: $14.45 billion vs. $13.79 billion expected The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera , to counter waning Covid product sales and declines from older drugs.…